METHODS.
Cell viability was measured by Annexin-FITC and PI staining and FACScan flow cytometry. Intracellular GSH was measured using the Glutathione Assay Kit (CalBiochem). H 2 O 2 and O -2 production were measured by flow cytometry using H 2 DCFDA and hydroethidine (Molecular Probes), respectively. Mitochondrial membrane potential (∆Ψ m ) was measured by flow cytometry using TMRE (Molecular Probes). Bone marrow (BM) aspirates were obtained from consenting MM patients and mononuclear cells isolated by ficoll purification. After 48h treatment, cells were triple stained with a mouse anti-human CD38-PE antibody, a mouse anti-human CD45-CyChrome antibody, and Annexin-FITC.
RESULTS AND DISCUSSION.
All three MM cell lines we tested, 8226/S, 8226/Dox40 (PgP+), U266, were sensitive to arsenic in a dose-dependent fashion. U266 cells stably expressing exogenous Bcl-x L were initially resistant to arsenic (2 µM), but less than 35% viable after 96h of treatment. Since AA is well tolerated in vivo, and has been shown to deplete GSH (3), a critical determinant of arsenic sensitivity (4), we tested the ability of AA (100 µM) to decrease GSH and potentiate arsenic cytotoxicity in MM cell lines. AA depleted GSH without affecting cell viability and the combination of AA and arsenic significantly increased apoptosis in all four cell lines. Similarly, AA alone had no effect on O -2 production, but the combination of AA and arsenic resulted in higher levels of O -2 than with arsenic alone. A similar pattern was observed when changes in ∆Ψ m were measured, consistent with arsenic exerting cellular cytotoxic effects via the generation of ROS, resulting in free radical cellular damage. Importantly, arsenic induced apoptosis (26.8%±3.9) in malignant plasma cells (CD38 + CD45 -) from MM patients, while normal BM cells (CD38 -) were relatively unaffected (7.2% ± 1.9). The combination of AA and arsenic was significantly more cytotoxic than etoposide in the CD38 +
CD45
-population (p<0.002). However, viabilities of CD38 -cells treated with arsenic, AA+arsenic, or etoposide were not significantly different. AA treatment alone has the potential to be a safe and effective chemosensitizing agent in an arsenic-based therapy. These pre-clinical studies have led to an NCI-sponsored Phase I/II trial (University of Miami) to assess the combination of arsenic and AA as a potential therapy for plateau and refractory MM patients.
